MICHAEL MULLAN, M.B.B.S. (MD), Ph.D.
Chief Executive Officer and Chief Scientific Officer
Archer Pharmaceuticals
mmullan@archerpharmaceuticals.com


Michael Mullan, M.B.B.S.(MD), Ph.D., has served as the Chief Executive Officer and Chief Scientific Officer for Archer Pharmaceuticals since its inception in 2008. He is also Chairman of the Archer Board. Dr. Mullan has previously served as CEO or CSO of both publicly traded and private drug development companies including the Roskamp Institute which he co-founded in 2003 with Dr. Fiona Crawford and Bob and Diane Roskamp.

Prior to becoming a US citizen, Dr. Mullan trained and worked in London, UK, as a physician where he co-discovered (and was co-inventor of the patents covering) the first-known genetic causes of Alzheimer’s disease in the amyloid gene.

Throughout his career, Dr. Mullan has received major grants and contracts from private, national and federal organizations to work on the causes and cures of Alzheimer’s disease.

Dr. Mullan earned his medical degree from The Royal Free Hospital Medical School, University of London and his Ph.D. in the molecular genetics of Alzheimer’s Disease from St. Mary’s Hospital Medical School, University of London.